Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30657511 | 1.00 | CYP11B2 (0.72) | CYP11B2CYP11B1 | |
| SCHEMBL20338390 | 0.89 | CYP11B2 (0.72) | CYP11B2CYP11B1 | |
| SCHEMBL20338199 | 0.84 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL30657532 | 0.84 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL20338248 | 0.82 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL30657515 | 0.82 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL20338273 | 0.80 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL20338302 | 0.80 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL30854037 | 0.80 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL20338174 | 0.78 | CYP11B2 (1.00) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| EP-4311577-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Ji Xing Pharmaceuticals Hong Kong Limited (HK) | 2024-01-31 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| CN-110691598-A | Metalloenzyme inhibitor compounds | 赛列尼蒂治疗(百慕大)有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3562487-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2019-01-10 | — | — | US | disclosed |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-10-02 | — | — | US | disclosed |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| WO-2018125800-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | CYP11B2 1/4885CYP11B1 2/4885 |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | CYP11B2 500/4885CYP11B1 481/4885 |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885 |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885 |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885 |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.